Nicolas Raposo

Nicolas Raposo

Auto-generated profile, based on publicly available information

Nicolas Raposo

Department of Neurology Toulouse University Hospital Toulouse France

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2010 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
NRN. Raposo
N. Raposo
AVA. Viguier
A. Viguier
VCV. Cuvinciuc
V. Cuvinciuc
LCL. Calviere
L. Calviere
CCC. Cognard
C. Cognard
VLV. Larrue
V. Larrue

16 November 2022 in Annals of Neurology
Verified
Journal Article
Open access
NRNicolas Raposo
Nicolas Raposo
MZMaria Clara Zanon Zotin
Maria Clara Zanon Zotin
DSDavid Seiffge
David Seiffge
Qi LiQi Li
Qi Li
MGMartina B. Goeldlin
Martina B. Goeldlin
AVAnand Viswanathan
Anand Viswanathan
Objective: Determining the underlying causes of intracerebral hemorrhage (ICH) is of major importance, because risk factors, prognosis, and management differ by ICH subtype. We developed a new causal CLASsification system for ICH Subtypes, termed CLAS‐ICH, based on recent advances in neuroimaging.Methods: CLAS‐ICH defines 5 ICH subtypes: arteriolosclerosis, cerebral amyloid angiopathy, mixed small vessel disease (SVD), other rare forms of SVD (genetic SVD and others), and secondary causes (macrovascular causes, tumor, and other rare causes). Every patient is scored in each category according to the level of diagnostic evidence: (1) well‐defined ICH subtype; (2) possible underlying disease; and (0) no evidence of the disease. We evaluated CLAS‐ICH in a derivation cohort of 113 patients with ICH from Massachusetts General Hospital, Boston, USA, and in a derivation cohort of 203 patients from Inselspital, Bern, Switzerland.Results: In the derivation cohort, a well‐defined ICH subtype could be identified in 74 (65.5%) patients, including 24 (21.2%) with arteriolosclerosis, 23 (20.4%) with cerebral amyloid angiopathy, 18 (15.9%) with mixed SVD, and 9 (8.0%) with a secondary cause. One or more possible causes were identified in 42 (37.2%) patients. Interobserver agreement was excellent for each category (kappa value ranging from 0.86 to 1.00). Despite substantial differences in imaging modalities, we obtained similar results in the validation cohort.Interpretation: CLAS‐ICH is a simple and reliable classification system for ICH subtyping, that captures overlap between causes and the level of diagnostic evidence. CLAS‐ICH may guide clinicians to identify ICH causes, and improve ICH classification in multicenter studies. ANN NEUROL 2023;93:16–28

12 September 2019 in International Journal of Stroke
Verified
Journal Article
Closed access
PDF file
ACAndreas Charidimou
Andreas Charidimou
MFMatthew P Frosch
Matthew P Frosch
RSRustam Al-Shahi Salman
Rustam Al-Shahi Salman
JBJean-Claude Baron
Jean-Claude Baron
CCCharlotte Cordonnier
Charlotte Cordonnier
FAfor the International CAA Association
for the International CAA Association
Rationale: The Boston criteria are used worldwide for the in vivo diagnosis of cerebral amyloid angiopathy and are the basis for clinical decision-making and research in the field. Given substantial advances in cerebral amyloid angiopathy's clinical aspects and MRI biomarkers, we designed a multicenter study within the International cerebral amyloid angiopathy Association aimed at further validating the diagnostic accuracy of the Boston and potentially improving and updating them. Aim: We aim to derive and validate an updated “version 2.0” of the Boston criteria across the spectrum of cerebral amyloid angiopathy-related presentations and MRI biomarkers. Sample size estimates: Participating centers with suitable available data (see Methods) were identified from existing collaborations and an open invitation to the International Cerebral Amyloid Angiopathy Association emailing list. Our study sample will include: (1) a derivation cohort – Massachusetts General Hospital (MGH), Boston cases from inception to 2012 (∼150 patients); (2) temporal external validation cohort – MGH, Boston cases from 2012 to 2018 (∼100 patients); and (3) geographical external validation cohort – non-Boston cases (∼85 patients). Methods and design: Multicenter collaborative study. We will collect and analyze data from patients' age ≥ 50 with any potential sporadic cerebral amyloid angiopathy-related clinical presentations (spontaneous intracerebral hemorrhage, transient focal neurological episodes and cognitive impairment), available brain MRI (“index test”), and histopathologic assessment for cerebral amyloid angiopathy (“reference standard” for diagnosis). Trained raters will assess MRI for all prespecified hemorrhagic and non-hemorrhagic small vessel disease markers of interest, according to validated criteria and a prespecified protocol, masked to clinical and histopathologic features. Brain tissue samples will be rated for cerebral amyloid angiopathy, defined as Vonsattel grade ≥2 for whole brain autopsies and ≥1 for cortical biopsies or hematoma evacuation. Based on our estimated available sample size, we will undertake pre-specified cohort splitting as above. We will: (a) pre-specify variables and statistical cut-offs; (b) examine univariable and multivariable associations; and (c) then assess classification measures (sensitivity, specificity etc.) for each MRI biomarker individually, in relation to the cerebral amyloid angiopathy diagnosis reference standard on neuropathology in a derivation cohort. The MRI biomarkers strongly associated with cerebral amyloid angiopathy diagnosis will be selected for inclusion in provisional (probable and possible cerebral amyloid angiopathy) Boston criteria v2.0 and validated using appropriate metrics and models. Study outcomes: Boston criteria v2.0 for clinical cerebral amyloid angiopathy diagnosis. Discussion: This work aims to potentially update and improve the diagnostic test accuracy of the Boston criteria for cerebral amyloid angiopathy and to provide wider validation of the criteria in a large sample. We envision that this work will meet the needs of clinicians and investigators and help accelerate progress towards better treatment of cerebral amyloid angiopathy.

3 July 2021 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
PSPierre Seners
Pierre Seners
COCatherine Oppenheim
Catherine Oppenheim
GTGuillaume Turc
Guillaume Turc
JAJean‐François Albucher
Jean‐François Albucher
AGAdrien Guenego
Adrien Guenego
TIthe FRAME investigators
the FRAME investigators

4 March 2021 in American Journal of Neuroradiology
Verified
Journal Article
Closed access
PDF file
NRN. Raposo
N. Raposo
MZM.C. Zanon Zotin
M.C. Zanon Zotin
DSD. Schoemaker
D. Schoemaker
LXL. Xiong
L. Xiong
PFP. Fotiadis
P. Fotiadis
AVA. Viswanathan
A. Viswanathan
BACKGROUND AND PURPOSE: Whole-brain network connectivity has been shown to be a useful biomarker of cerebral amyloid angiopathy and related cognitive impairment. We evaluated an automated DTI-based method, peak width of skeletonized mean diffusivity, in cerebral amyloid angiopathy, together with its association with conventional MRI markers and cognitive functions. MATERIALS AND METHODS: We included 24 subjects (mean age, 74.7 [SD, 6.0] years) with probable cerebral amyloid angiopathy and mild cognitive impairment and 62 patients with MCI not attributable to cerebral amyloid angiopathy (non-cerebral amyloid angiopathy–mild cognitive impairment). We compared peak width of skeletonized mean diffusivity between subjects with cerebral amyloid angiopathy–mild cognitive impairment and non-cerebral amyloid angiopathy–mild cognitive impairment and explored its associations with cognitive functions and conventional markers of cerebral small-vessel disease, using linear regression models. RESULTS: Subjects with Cerebral amyloid angiopathy–mild cognitive impairment showed increased peak width of skeletonized mean diffusivity in comparison to those with non-cerebral amyloid angiopathy–mild cognitive impairment (P < .001). Peak width of skeletonized mean diffusivity values were correlated with the volume of white matter hyperintensities in both groups. Higher peak width of skeletonized mean diffusivity was associated with worse performance in processing speed among patients with cerebral amyloid angiopathy, after adjusting for other MRI markers of cerebral small vessel disease. The peak width of skeletonized mean diffusivity did not correlate with cognitive functions among those with non-cerebral amyloid angiopathy–mild cognitive impairment. CONCLUSIONS: Peak width of skeletonized mean diffusivity is altered in cerebral amyloid angiopathy and is associated with performance in processing speed. This DTI-based method may reflect the degree of white matter structural disruption in cerebral amyloid angiopathy and could be a useful biomarker for cognition in this population.

4 February 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
NRNicolas Raposo
Nicolas Raposo
ACAndreas Charidimou
Andreas Charidimou
DRDuangnapa Roongpiboonsopit
Duangnapa Roongpiboonsopit
MOMichelle Onyekaba
Michelle Onyekaba
MGM. Edip Gurol
M. Edip Gurol
AVAnand Viswanathan
Anand Viswanathan
Objective To investigate whether acute convexity subarachnoid hemorrhage (cSAH) associated with acute lobar intracerebral hemorrhage (ICH) increases the risk of ICH recurrence in patients with cerebral amyloid angiopathy (CAA). Methods We analyzed data from a prospective cohort of consecutive survivors of acute spontaneous lobar ICH fulfilling the Boston criteria for possible or probable CAA (CAA-ICH). We analyzed baseline clinical and MRI data, including cSAH (categorized as adjacent or remote from ICH on a standardized scale), cortical superficial siderosis (cSS), and other CAA MRI markers. Multivariable Cox regression models were used to assess the association between cSAH and recurrent symptomatic ICH during follow-up. Results We included 261 CAA-ICH survivors (mean age 76.2 ± 8.7 years). Of them, 166 (63.6%, 95% confidence interval [CI] 57.7%–69.5%) had cSAH on baseline MRI. During a median follow-up of 28.3 (interquartile range 7.2–57.0) months, 54 (20.7%) patients experienced a recurrent lobar ICH. In Cox regression, any cSAH, adjacent cSAH, and remote cSAH were independent predictors of recurrent ICH after adjustment for other confounders, including cSS. Incidence rate of recurrent ICH in patients with cSAH was 9.9 per 100 person-years (95% CI 7.3–13.0) compared with 1.2 per 100 person-years (95% CI 0.3–3.2) in those without cSAH (adjusted hazard ratio 7.5, 95% CI 2.6–21.1). Conclusion In patients with CAA-related acute ICH, cSAH (adjacent or remote from lobar ICH) is commonly observed and heralds an increased risk of recurrent ICH. cSAH may help stratify bleeding risk and should be assessed along with cSS for prognosis and clinical management.